CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation.
CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation.
复制标题
DOI：
10.1002/ijc.31900
复制
发表时间：
2019-04-15
影响因子：
6.4
通讯作者：
Kaaks R
中科院分区：
文献类型：
--
作者：
Honda K;Katzke VA;Hüsing A;Okaya S;Shoji H;Onidani K;Olsen A;Tjønneland A;Overvad K;Weiderpass E;Vineis P;Muller D;Tsilidis K;Palli D;Pala V;Tumino R;Naccarati A;Panico S;Aleksandrova K;Boeing H;Bueno-de-Mesquita HB;Peeters PH;Trichopoulou A;Lagiou P;Khaw KT;Wareham N;Travis RC;Merino S;Duell EJ;Rodríguez-Barranco M;Chirlaque MD;Barricarte A;Rebours V;Boutron-Ruault MC;Romana Mancini F;Brennan P;Scelo G;Manjer J;Sund M;Öhlund D;Canzian F;Kaaks R
近期，我们在胰腺癌患者中发现了载脂蛋白A2（ApoA2）独特的加工模式。本研究首次对ApoA2异构体（“ApoA2 - ATQ/AT”）单独以及与糖类抗原19 - 9（CA19 - 9）联合作为胰腺癌早期检测生物标志物进行了前瞻性评估。
我们在欧洲EPIC队列中的156例胰腺癌患者和217例匹配的对照者中，使用诊断前长达60个月收集的血浆样本，对CA19 - 9和ApoA2 - ATQ/AT进行了酶联免疫吸附测定（ELISA）测量。按滞后时间分层计算了风险评分的检测判别统计量。
对于CA19 - 9，在单变量标志物分析中，区分未来胰腺癌患者和无癌个体的血浆样本在诊断前≤6个月采集时的C统计量为0.80，在>6 - 18个月时为0.71；对于ApoA2 - ATQ/AT，C统计量分别为0.62和0.65。基于ApoA2 - ATQ/AT加CA19 - 9的联合模型在>6 - 18个月（C = 0.74，相较于单独的CA19 - 9的0.71，p = 0.022）和≤18个月（C = 0.75，相较于0.74，p = 0.022）内显著提高了判别能力。在特异性为98%的情况下，对于滞后时间为≤6个月、>6 - 18个月或≤18个月，CA19 - 9与ApoA2 - ATQ/AT联合的敏感度分别为57%、36%和43%，而单独的CA19 - 9分别为50%、29%和36%。
与单独使用CA19 - 9相比，CA19 - 9和ApoA2 - ATQ/AT的联合可能在常规护理下将胰腺癌的诊断提前至18个月，并可能为影像学检查之前的胰腺癌检测提供一种有用的首要检测手段。
Recently, we identified unique processing patterns of apolipoprotein A2 (ApoA2) in patients with pancreatic cancer. This study provides a first prospective evaluation of an ApoA2 isoform (“ApoA2-ATQ/AT”), alone and in combination with carbohydrate antigen 19-9 (CA19-9), as an early detection biomarker for pancreatic cancer. We performed ELISA measurements of CA19-9 and ApoA2-ATQ/AT in 156 patients with pancreatic cancer and 217 matched controls within the European EPIC cohort, using plasma samples collected up to 60 months prior to diagnosis. The detection discrimination statistics were calculated for risk scores by strata of lag-time. For CA19-9, in univariate marker analyses, C-statistics to distinguish future pancreatic cancer patients from cancer-free individuals were 0.80 for plasma taken ≤6 months before diagnosis, and 0.71 for >6-18 months; for ApoA2-ATQ/AT, C-statistics were 0.62, and 0.65, respectively. Joint models based on ApoA2-ATQ/AT plus CA19-9 significantly improved discrimination within >6-18 months (C = 0.74 vs. 0.71 for CA19-9 alone, p = 0.022) and ≤18 months (C = 0.75 vs. 0.74, p = 0.022). At 98% specificity, and for lag times of ≤6, >6-18 or ≤18 months, sensitivities were 57%, 36% and 43% for CA19-9 combined with ApoA2-ATQ/AT, respectively, vs. 50%, 29% and 36% for CA19-9 alone. Compared to CA19-9 alone, the combination of CA19-9 and ApoA2-ATQ/AT may improve detection of pancreatic cancer up to 18 months prior to diagnosis under usual care, and may provide a useful first measure for pancreatic cancer detection prior to imaging.
登录
查看更多内容
影响因子：
3.7
作者：
Nolen BM;Brand RE;Prosser D;Velikokhatnaya L;Allen PJ;Zeh HJ;Grizzle WE;Huang Y;Lomakin A;Lokshin AE
通讯作者：
Lokshin AE
影响因子：
2
作者：
Pencina, Michael J.;D'Agostino, Ralph B., Sr.;Steyerberg, Ewout W.
通讯作者：
Steyerberg, Ewout W.
影响因子：
3.7
作者：
Honda K;Okusaka T;Felix K;Nakamori S;Sata N;Nagai H;Ioka T;Tsuchida A;Shimahara T;Shimahara M;Yasunami Y;Kuwabara H;Sakuma T;Otsuka Y;Ota N;Shitashige M;Kosuge T;Büchler MW;Yamada T
通讯作者：
Yamada T
DOI：
10.1158/1078-0432.ccr-14-0365
发表时间：
2015-02-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
O'Brien DP;Sandanayake NS;Jenkinson C;Gentry-Maharaj A;Apostolidou S;Fourkala EO;Camuzeaux S;Blyuss O;Gunu R;Dawnay A;Zaikin A;Smith RC;Jacobs IJ;Menon U;Costello E;Pereira SP;Timms JF
通讯作者：
Timms JF
影响因子：
2.2
作者：
Honda K;Srivastava S
通讯作者：
Srivastava S